Product Description
Hanmi Company Limited is developing Mosapride as a treatment for irritable bowel syndrome without diarrhea. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01505777)
Mechanisms of Action: 5-HT4 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | China | Dominican Republic | Egypt | India | Japan | Korea | Lebanon | Mexico | Pakistan | Philippines | Sri Lanka | Taiwan | Thailand | Ukraine | Uruguay | Vietnam
Approved Indications: None
Company: Hanmi
Company Location: Western America
Company Founding Year: 1973
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Gastroparesis|Constipation|Irritable Bowel Syndrome|Ileus|Type 2 Diabetes|Gastroesophageal Reflux|Esophagitis, Peptic
Phase 3: Gastrointestinal Cancer|Ileus
Phase 2: Diarrhea|Irritable Bowel Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2400088624 |
ChiCTR2400088624 | N/A |
Recruiting |
Constipation |
2026-12-31 |
|||
ChiCTR2500107484 |
ChiCTR2500107484 | N/A |
Recruiting |
Other |
2026-11-30 |
|||
ChiCTR2400079843 |
ChiCTR2400079843 | N/A |
Not yet recruiting |
General Diabetes |
2026-06-01 |
2024-01-15 |
Treatments |
|
ChiCTR2400082798 |
ChiCTR2400082798 | N/A |
Not yet recruiting |
Dyspepsia |
2024-12-01 |
2024-04-10 |
Treatments |
|
NCT04905147 |
COA.MURA2021/328 | N/A |
Unknown status |
Colorectal Cancer|Ileus |
2023-07-31 |
2023-12-02 |
||
ChiCTR2100054269 |
ChiCTR2100054269 | N/A |
Recruiting |
Dyspepsia |
2022-12-31 |
|||
ChiCTR2000036761 |
ChiCTR2000036761 | N/A |
Not yet recruiting |
Gastroesophageal Reflux |
2022-09-30 |
|||
ChiCTR2000030097 |
ChiCTR2000030097 | N/A |
Not yet recruiting |
Gastritis |
2020-12-24 |
|||
NCT03600974 |
EAISMLP | N/A |
Unknown status |
Bile Reflux |
2020-07-01 |
2021-07-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT02984930 |
NCT02984930 | N/A |
Unknown status |
Esophagitis, Peptic|Gastroesophageal Reflux |
2018-07-01 |
2019-03-21 |
Treatments |
|
ChiCTR-OOB-15006348 |
ChiCTR-OOB-15006348 | N/A |
Recruiting |
Constipation |
2017-04-01 |
|||
ChiCTR1900021574 |
ChiCTR1900021574 | N/A |
Completed |
Dyspepsia |
2016-12-31 |
|||
NCT01505777 |
HM-MEMO-201 | P2 |
Completed |
Irritable Bowel Syndrome|Diarrhea |
2012-06-01 |
2019-03-19 |
Treatments |
|
NCT03477266 |
[email protected] | P3 |
Completed |
Ileus |
2018-06-01 |
2019-03-22 |
Treatments |
|
NCT01284764 |
SMW | P3 |
Completed |
Gastrointestinal Cancer |
2011-07-01 |
2019-03-19 |
||
NCT02433847 |
Mosa_GIFx_1.0 | P4 |
Unknown status |
Constipation|Irritable Bowel Syndrome |
2016-04-01 |
2019-03-20 |
Treatments |
|
NCT02056405 |
ILEUS | P4 |
Unknown status |
Ileus |
2016-12-01 |
2019-03-20 |
Treatments |
|
NCT02606617 |
Mosapride Comparing Placebo | P4 |
Unknown status |
Type 2 Diabetes |
2016-09-01 |
2019-03-20 |
||
NCT02264587 |
MDGP | P4 |
Unknown status |
Gastroparesis |
2015-09-01 |
2022-07-22 |
Primary Endpoints|Treatments |
|
NCT00729339 |
OMCP-97-011 | P4 |
Completed |
Esophagitis, Peptic|Gastroesophageal Reflux |
2009-04-01 |
2019-03-18 |